Research ArticleArticle
Which Factors Influence Radiographic Progression During Treatment with Tumor Necrosis Factor Inhibitors in Clinical Practice? Results from 930 Patients with Rheumatoid Arthritis in the Nationwide Danish DANBIO Registry
Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Pernille Bøyesen, Niels Steen Krogh, Anja Thormann, Ulrik Tarp, Uta Engling Poulsen, Jakob Espesen, Annette Schlemmer, Niels Graudal, Gina Kollerup, Dorte Vendelbo Jensen, Ole Rintek Madsen, Bente Glintborg, Torben Christensen, Hanne Lindegaard, Wolfgang Bøhme, Annette Hansen, Anne Rødgaard Andersen and Merete Lund Hetland
The Journal of Rheumatology October 2014, jrheum.131299; DOI: https://doi.org/10.3899/jrheum.131299
Lykke Midtbøll Ørnbjerg
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Mikkel Østergaard
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Pernille Bøyesen
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Niels Steen Krogh
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Anja Thormann
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Ulrik Tarp
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Uta Engling Poulsen
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Jakob Espesen
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Annette Schlemmer
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Niels Graudal
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Gina Kollerup
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Dorte Vendelbo Jensen
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Ole Rintek Madsen
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Bente Glintborg
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Torben Christensen
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Hanne Lindegaard
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Wolfgang Bøhme
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Annette Hansen
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Anne Rødgaard Andersen
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
Merete Lund Hetland
From the DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Zitelab Aps, Copenhagen; Department of Rheumatology, Aarhus University Hospital, Aarhus; Rheumatism Hospital, University of Southern Denmark, Gråsten; Department of Internal Medicine, Lillebælt Hospital, Vejle; Department of Rheumatology, Aarhus University Hospital, Aalborg; Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; Department of Rheumatology, Copenhagen University Hospital Frederiksberg, Copenhagen; Department of Rheumatology, Helsingør Hospital, Helsingør; Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup; Department of Internal Medicine, Holbæk Hospital, Holbæk; Department of Rheumatology, Copenhagen University Hospital Slagelse, Slagelse; Department of Rheumatology, Odense University Hospital, Odense; Department of Medicine, Hospital of South West Jutland, Esbjerg; Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, Glostrup, Denmark. Supported by Danish Regions (i.e., the hospital owners) who gave financial support to DANBIO. Janssen Biologics (formerly Centocor) supported the collection of radiographs with an unrestricted grant while Abbott, Pfizer (formerly Wyeth), MSD (formerly Schering-Plough; since 2004), Bristol-Myers Squibb, Roche (since 2006), and UCB-Nordic (since 2007) have supported DANBIO with unrestricted grants. The sponsors have had no influence on data collection, analysis, or publication. Dr. Ørnbjerg’s work was financed by a clinical PhD grant from the University of Copenhagen. MØ has received consulting fees, speaking fees, or research grants from Abbott, Amgen, Bristol-Myers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Genmab, Glaxo-Smith-Kline, MSD, Mundipharma, Novo, Pfizer, Roche, Schering-Plough, Takeda, UCB, and Wyeth. UT has received consulting fees, speaking fees, or research grants from Roche, Schering-Plough, Abbott, and MSD. GK has received consulting fees, speaking fees, or research grants from MSD. ORM has received consulting fees, speaking fees, and research grants from Abbott, MSD, Pfizer, UCB, Bristol-Myers Squibb, Amgen, and Roche. HL has received consulting fees, speaking fees, or research grants from Roche, MSD, and Mundipharma. AH has received consulting fees, speaking fees, or research grants from Abbott, MSD, and BMS. MLH has received consulting fees, speaking fees, or research grants from Abbott, Bristol-Myers Squibb, Centocor/Janssen, Glaxo-Smith-Kline, MSD/Schering-Plough, Pfizer/Wyeth, Roche, and UCB. L.M. Ørnbjerg, MD; M. Østergaard, MD, PhD, DMSc; A. Thormann, MD; M.L. Hetland, MD, PhD, DMSc, DANBIO registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen; P. Bøyesen, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; N.S. Krogh, consultant, Zitelab Aps; U. Tarp, MD, DMSc, Department of Rheumatology, Aarhus University Hospital; U.E. Poulsen, MD, Rheumatism Hospital, University of Southern Denmark; J. Espesen, MD, Department of Internal Medicine, Lillebælt Hospital; A. Schlemmer, MD, Department of Rheumatology, Århus University Hospital, Aalborg; N. Graudal, MD, DMSc, Department of Rheumatology, Copenhagen University Hospital Rigshospitalet; G. Kollerup, MD, PhD, Department of Rheumatology, Copenhagen University Hospital Frederiksberg; D.V. Jensen, MD, Department of Rheumatology, Helsingør Hospital; O.R. Madsen, MD, PhD, DMSc; A. Hansen, MD, Department of Rheumatology/C, Copenhagen University Hospital Gentofte; B. Glintborg, MD, PhD, Department of Internal Medicine, Holbæk Hospital; T.G. Christensen, MD, Department of Rheumatology, Copenhagen University Hospital Slagelse; H. Lindegaard, MD, PhD, Department of Rheumatology, Odense University Hospital; W. Bøhme, MD, Department of Medicine, Hospital of South West Jutland; A.R. Andersen, MD, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup. Address correspondence to Dr. L.M. Ørnbjerg, DANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark. E-mail: lykke@oernbjerg.dk. Accepted for publication August 6, 2014.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Which Factors Influence Radiographic Progression During Treatment with Tumor Necrosis Factor Inhibitors in Clinical Practice? Results from 930 Patients with Rheumatoid Arthritis in the Nationwide Danish DANBIO Registry
Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Pernille Bøyesen, Niels Steen Krogh, Anja Thormann, Ulrik Tarp, Uta Engling Poulsen, Jakob Espesen, Annette Schlemmer, Niels Graudal, Gina Kollerup, Dorte Vendelbo Jensen, Ole Rintek Madsen, Bente Glintborg, Torben Christensen, Hanne Lindegaard, Wolfgang Bøhme, Annette Hansen, Anne Rødgaard Andersen, Merete Lund Hetland
The Journal of Rheumatology Oct 2014, jrheum.131299; DOI: 10.3899/jrheum.131299
Which Factors Influence Radiographic Progression During Treatment with Tumor Necrosis Factor Inhibitors in Clinical Practice? Results from 930 Patients with Rheumatoid Arthritis in the Nationwide Danish DANBIO Registry
Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Pernille Bøyesen, Niels Steen Krogh, Anja Thormann, Ulrik Tarp, Uta Engling Poulsen, Jakob Espesen, Annette Schlemmer, Niels Graudal, Gina Kollerup, Dorte Vendelbo Jensen, Ole Rintek Madsen, Bente Glintborg, Torben Christensen, Hanne Lindegaard, Wolfgang Bøhme, Annette Hansen, Anne Rødgaard Andersen, Merete Lund Hetland
The Journal of Rheumatology Oct 2014, jrheum.131299; DOI: 10.3899/jrheum.131299